About this item:

358 Views | 253 Downloads

Author Notes:

Correspondence: V. D. Cantos, MD, Grady Health System Ponce de Leon Center, 341 Ponce de Leon Ave NE, Atlanta, GA, 30308 (vcantos@emory.edu).

All authors: no reported conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Subjects:

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Infectious Diseases
  • HIV
  • KSHV inflammatory cytokine syndrome
  • KICS
  • MULTICENTRIC CASTLEMAN DISEASE
  • SYNDROME KICS
  • INTERLEUKIN-6
  • RITUXIMAB
  • MALIGNANCIES
  • MAINTENANCE
  • INFECTION
  • FEATURES

Experience with Kaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome in a Large Urban HIV Clinic in the United States: Case Series and Literature Review

Tools:

Journal Title:

Open Forum Infectious Diseases

Volume:

Volume 4, Number 4

Publisher:

, Pages ofx196-ofx196

Type of Work:

Article | Final Publisher PDF

Abstract:

In 2010, a new entity, characterized by the classical signs and symptoms of Kaposi sarcoma herpesvirus-associated multicentric Castleman's disease (KSHV-MCD) in the absence of pathologic evidence of MCD, was described in individuals living with HIV. This syndrome was named KSHV inflammatory cytokine syndrome (KICS). It carries mortality rates of up to 60%. To date, there are no standard therapies. Treatment regimens studied in clinical trials for MCD disease are used in cases of KICS.

Copyright information:

© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote